Multiple Myeloma
Multiple Myeloma
We’re here for you. Call us at 844-346-7222 or
find a clinical trial
If you have any questions or are interested in participating in one of our Clinical Trials, please take note of the associated protocol number and contact our team at (201) 518-3587, or email us at email.
43
Clinical Trials
Multiple Myeloma
Phase I
Enrolling
nct/study# NCT04973605 / BGB-11417-105
A Phase 1b/2 Dose-Escalation and Cohort-Expansion Study to Determine the Safety and Efficacy of BGB-11417 as Monotherapy, in Combination With Dexamethasone, Dexamethasone/Carfilzomib, Dexamethasone/Daratumumab, and Dexamethasone/Pomalidomide in Patients With Relapsed/Refractory Multiple Myeloma and t(11;14)
Learn More
Multiple Myeloma
Phase II
Enrolling
nct/study# NCT06356571 / LPS18183
Sanofi LPS18183: A single-arm, open-label, Phase 2 study evaluating subcutaneous administration of isatuximab, administered by an On Body Delivery System, in combination with weekly carfilzomib and dexamethasone in adult participants with relapsed and/or refractory multiple myeloma (RRMM).
Learn More
Multiple Myeloma
N/A
Enrolling
nct/study# N/A / BI-SPECIFIC-T-CELL-OUTCOMES
Outcomes of Multiple Myeloma Patients who are Refractory to Bi-Specific T-Cell Engagers
Learn More
Multiple Myeloma
N/A
Enrolling
nct/study# N/A / BIOLOGICAL-SPECIMEN
Collection of Biological Specimens from Volunteers or Patients with Multiple Myeloma and other Plasma Cell Dyscrasias
Learn More
Multiple Myeloma
N/A
Enrolling
nct/study# N/A / BTKI/IIT
Use of Bruton tyrosine kinase inhibitors (BTKI) in patients with Waldenstrom macroglobulinemia (WM) with neuropathy and Bing-Neel syndrome, and non-IgM lymphoplasmacytic lymphoma
Learn More
Multiple Myeloma
Phase I/II
Enrolling
nct/study# NCT05372354 / CA057-003
An Exploratory Phase 1b/2a Multicenter, Open-Label, Novel-Novel Combination Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of CC-92480 (BMS-986348) in Novel Therapeutic Combinations in Participants with Relapsed or Refractory Multiple Myeloma
Learn MoreWe are here for you
For more information or to schedule an appointment, call (844) 346-7222. You can also schedule an appointment by calling the RCCA location nearest you.
Regional Cancer Care Associates is one of fewer than 200 medical practices in the country selected to participate in the Oncology Care Model (OCM); a recent Medicare initiative aimed at improving care coordination and access to and quality of care for Medicare beneficiaries undergoing chemotherapy treatment.